NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) Given Consensus Rating of “Hold” by Analysts

NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) has earned an average recommendation of “Hold” from the five brokerages that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $7.3333.

Several equities analysts have issued reports on NMTC shares. Maxim Group set a $5.00 target price on NeuroOne Medical Technologies and gave the stock a “buy” rating in a research report on Friday, August 14th. Weiss Ratings downgraded shares of NeuroOne Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, August 21st.

Insider Transactions at NeuroOne Medical Technologies

In related news, insider David J. Wambeke acquired 33,333 shares of the company’s stock in a transaction that occurred on Thursday, August 27th. The stock was purchased at an average price of $2.01 per share, for a total transaction of $66,999.33. Following the transaction, the insider owned 199,999 shares in the company, valued at $401,997.99. This trade represents a 20.00% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Mark Christianson sold 10,000 shares of NeuroOne Medical Technologies stock in a transaction dated Tuesday, June 30th. The stock was sold at an average price of $3.18, for a total transaction of $31,800.00. Following the sale, the director owned 20,692 shares of the company’s stock, valued at approximately $65,800.56. This trade represents a 32.58% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 11.80% of the company’s stock.

Hedge Funds Weigh In On NeuroOne Medical Technologies

Several institutional investors have recently added to or reduced their stakes in NMTC. Susquehanna International Group LLP purchased a new position in shares of NeuroOne Medical Technologies during the 2nd quarter worth about $41,000. BlackRock Inc. purchased a new position in shares of NeuroOne Medical Technologies in the 2nd quarter valued at $76,000. Legato Capital Management LLC acquired a new stake in NeuroOne Medical Technologies in the 4th quarter valued at $34,000. Finally, Bard Associates Inc. purchased a new stake in shares of NeuroOne Medical Technologies in the second quarter worth about $929,000. 16.07% of the stock is currently owned by institutional investors and hedge funds.

NeuroOne Medical Technologies Trading Down 3.5%

Shares of NMTC stock opened at $1.36 on Friday. The company has a market capitalization of $12.39 million, a P/E ratio of -1.43 and a beta of 0.65. The business’s 50 day moving average is $1.85 and its two-hundred day moving average is $3.29. NeuroOne Medical Technologies has a twelve month low of $1.35 and a twelve month high of $6.96.

NeuroOne Medical Technologies (NASDAQ:NMTC) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.07). The company had revenue of $1.97 million for the quarter, compared to analyst estimates of $2.17 million. NeuroOne Medical Technologies had a negative return on equity of 128.12% and a negative net margin of 71.50%. As a group, equities analysts predict that NeuroOne Medical Technologies will post -0.39 earnings per share for the current fiscal year.

NeuroOne Medical Technologies Company Profile

NeuroOne Medical Technologies Corp. is a medical device company focused on developing advanced neural interface technologies for diagnostic and therapeutic applications in neurosurgery and neurology. The company’s core mission is to improve patient outcomes through next-generation electrode systems that enable high-resolution neural recording and targeted stimulation. By leveraging proprietary thin-film microelectrode arrays, NeuroOne aims to offer clinicians unprecedented single-unit precision during brain mapping procedures.

The company’s flagship platform, the EVO™ system, integrates thin-film neural electrodes with intraoperative monitoring hardware and software.